Rise Health & Wellness Peptides

1. Melanocortin Receptor Agonism: Binds to MC3-R and MC4-R receptors in the hypothalamus to stimulate sexual arousal centers.

2. Central Nervous System Targeting: Acts primarily through the CNS rather than the vascular system, distinguishing it from PDE5 inhibitors.

3. Neurotransmitter Modulation: Enhances dopamine and oxytocin signaling pathways to improve sexual desire, arousal, and pleasure response.

1. Female Sexual Dysfunction – Phase 3 Trial

• Findings: Improved sexual desire and satisfaction compared to placebo in women with HSDD
• PMID: 31675872

2. HSDD in Women – Clinical Trial

• Findings: Increased sexual function; generally well tolerated, with nausea as the most common side effect
• PMID: 29362639

3. Safety and Efficacy in HSDD

• Findings: Low incidence of serious adverse effects; effective in improving sexual desire
• PMID: 30703677

4. Randomized Controlled Trial in Women with HSDD

• Findings: Significant improvement in sexual satisfaction and libido versus placebo
• PMID: 30263140

5. Sexual Desire in Men

• Findings: Demonstrated benefits in male libido and erectile response, including in non-responders to traditional ED medications
• PMID: 25345518

6. Female Sexual Arousal Enhancement

• Findings: Pre-activity administration led to greater arousal and satisfaction in women with HSDD
• PMID: 30763424

7. Erectile Dysfunction in Men – Preclinical and Clinical Studies

• Findings: Central nervous system mechanism shows promise as an alternative ED therapy
• PMID: 24062352